VRDN-001, a thyroid eye disease (TED) therapy currently under review, can elicit a rapid and sustained increases in insulin-like growth factor-1 (IGF-1) serum levels in both healthy volunteers and patients with TED when administered intravenously, according to a poster presented at the North American Neuro-Ophthalmology Society’s 49th annual meeting in Orlando, FL, help March 11-16, 2023.1 The research shows the therapy’s clinically meaningful effect proptosis, inflammation, and diplopia at 6 weeks, following 2 infusions of 3, 10, or 20 mg/kg of VRDN-001.1
The researchers randomly assigned participants to receive 2 intravenous infusions 3 weeks apart of either placebo or VRDN-001. Participants included 13 healthy volunteers (mean age, 49 [range: 25 to 73] years; 8 men, 5 women; placebo [n=3], 3 mg/kg [n=3], 10 mg/kg [n=3], or 20 mg/kg [n=4]) and 8 patients with TED (mean age, 41 [range: 27 to 59] years, 3 men, 5 women; placebo (n=2) or 10 mg/kg of VRDN-001 [n=6]). The investigators assessed the IGF-1 serum levels for 50 days.1
All patients injected with any dose of VRDN-001 demonstrated rapid, sustained, and similar increases in IGF-1 serum levels. These serum increases all occurred within 1 day of treatment and were sustained for 50 days. For the healthy volunteer participants, mean IGF-1 serum levels increased within a day of the first infusion, reaching 3- to 5-fold above baseline, and continued to increase following a second infusion, eventually reaching 5- to 7-fold above the baseline.1
In the patients with TED, mean IGF-1 serum levels increased from 139 ng/mL at baseline to 853 ng/mL after 2 infusions, representing a 6-fold increase.
No increases in IGF-1 serum levels occurred for placebo-treated participants in either group.1
“In TED patients, rapid and clinically meaningful improvement was seen in proptosis, inflammation, and diplopia at 6 weeks,” according to the presenters.
VRDN-001, an antagonist antibody to IGF-1 receptors, has a distinct mutational signature and a more complete antagonism of IGF-1 mediated signaling, as well as different binding and functional antagonism characteristics when compared with teprotumumab, according to a second poster presented at the conference.2 That poster explains that VRDN-001 has a similar binding site to teprotumumab, but does not exhibit sensitivity to certain mutations in the IGF-1 binding region, while teprotumumab does.2
A new Phase III trial into the drug, Thrive (ClinicalTrials.gov Identifier: NCT05176639), “will assess efficacy and safety of VRDN-001, a full antagonist antibody to IGF-1R, in both a standard 8-infusion regimen and a shortened 5-infusion regimen to define treatment regimens that balance efficacy, safety, and patient treatment burden.”3
March 29, 2021
March 24, 2021
March 24, 2021
March 24, 2021
March 24, 2021
March 24, 2021
References:
- Foster K, Dickinson B, Summerfelt R, She A, Bedian V, Kat B. VRDN-001, a full antagonist antibody to igf-1 receptor in development for thyroid eye disease (ted): interim phase 1/2 pharmacodynamic results. Presented at: North American Neuro-Ophthalmology Society 49th Annual Meeting; March 11-16, 2023. Poster 298.
- Zhao Y, Tsai J, Newell R, Bedia V. VRDN-001, a full antagonist antibody to igf-1r in development for thyroid eye disease (ted), binds to a distinct epitope from teprotumumab. Presented at: North American Neuro-Ophthalmology Society 49th Annual Meeting; March 11-16, 2023. Poster 297.
- Katz B, Summerfelt R, O’Shaughnessy D, Douglas RS. THRIVE phase 3 trial of VRDN-001: a full antagonist antibody to the igf-1 receptor for thyroid eye disease (TED). Presented at: North American Neuro-Ophthalmology Society 49th Annual Meeting; March 11-16, 2023. Poster 296.